In addition to Stephen Doberstein, 6 other NKTR executives reported Sell trades in the last month.
The company has a one year high of $19.98 and a one year low of $10.52. Currently, Nektar Therapeutics has an average volume of 1.2M.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $20.80, reflecting a -33.0% downside.
In the last 30 days, insiders have sold $44.28K worth of NKTR shares and purchased $202.5K worth of NKTR shares. The insider sentiment on Nektar Therapeutics has been positive according to 70 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.